Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now!

Epilepsy

View All

Seizures Alert Devices Preventing Epilepsy
Role of Seizures Alert and Monitoring Devices in the Management of Epilepsy

As per the WHO, roughly 50 million people worldwide have Epilepsy. The burden of Epilepsy is growing in almost every geographic region. According to the Global Burden of Disease report on the burden of neurological diseases, it is observed that idiopathic epilepsy accounted for 5% of all neurological DALYs and 1.3%...

Find More

Epileptic Encephalopathy
Epidiolex vs Fintepla: Fight in Rare Epilepsies

Epidiolex (Jazz Pharma) and Fintepla (Zogenix - Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74....

Find More

MedTech News and Insights for Check-Cap, Curebase, Brainlab, and GE
Check-Cap’s Pivotal Trial for C-Scan; Curebase and Flow Neuroscience’s tDCS Device; Brainlab Acquires Majority Share in medPhoton; GE Healthcare to Invest in Pulsenmore; Medtronic’s Drug-Eluting Coronary Stent System; Remedee’ Endorphin Stimulation Solution;

Check-Cap Initiated the US Pivotal Trial for C-Scan® On May 11, 2022, Check-Cap Ltd., a clinical-stage diagnostic company initiated the US pivotal trial for C-Scan® at Mayo Clinic in Rochester Minnesota. C-Scan is the first and only patient-friendly, preparation-free screening test to detect polyps before they m...

Find More

Pharma News and Updates for Sanofi ViiV Argenx Novartis UCB Kyowa
Sanofi’s Rare Disease Drug Xenpozyme’ Approval; FDA Approves Novartis’ Pluvicto; AstraZeneca’s Imfinzi Trial Result; FDA’s Green Signal to Argenx’ Vyvgart; ViiV Healthcare and J&J’s HIV Treatment Cabenuva; UCB’s FINTEPLA Approval; Cullinan’s Update for CLN-081; MEI Pharma & Kyowa’s Zandelisib Approval

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...

Find More

Potential of Cannabidiol (CBD) as a Treatment Substance
Can Cannabinoids be an Effective Medicinal Substance?

Cannabidiol (CBD) is one of the 120 cannabinoids present naturally in cannabis plants. After tetrahydrocannabinol (THC), Cannabidiol is the second most prevalently available cannabinoid. Cannabidiol, an important component of medicinal marijuana, is either directly from the hemp plant or synthesized in a laboratory...

Find More

deep-brain-stimulation-devices-market
How Will New Discoveries of Deep Brain Stimulation Devices Transform the Pharma Domain?

Deep brain stimulation (DBS) is a surgical procedure that requires the implantation of a device capable of sending electrical impulses to the brain areas responsible for body movement. A DBS system is composed of the neuro-stimulator, leads, and extension. The electrodes are placed deep inside the brain and are lin...

Find More

Drug-resistant Epilepsy Market
Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape?

Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Known as Drug-resistant epilep...

Find More

Frequently Asked Questions About Epilepsy And Seizures
21 of the most common questions about Epilepsy

The term Epilepsy isn’t new. It’s been present in the air for centuries now, however, only a few are aware that it is one of the most common neurological diseases in the world. It affects around 50 million people worldwide. However, public awareness regarding Epilepsy is quite less and it can result in the ris...

Find More

Epilepsy Market
Ever-evolving Market Dynamics of Epilepsy – a silver lining!

Potential and growth of the current market The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects. The epilepsy market has witnessed several approvals in the l...

Find More

Alzheimer-Disease-Risk-Factors
The Question That Remains Unanswered: What Might Be Causing Alzheimer’s?

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...

Find More